Skip to main navigation Skip to search Skip to main content

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

  • Adrian Minson
  • , Nada Hamad
  • , Chan Y. Cheah
  • , Constantine Tam
  • , Piers Blombery
  • , David Westerman
  • , David Ritchie
  • , Huw Morgan
  • , Nicholas Holzwart
  • , Stephen Lade
  • , Mary Ann Anderson
  • , Amit Khot
  • , John F. Seymour
  • , Molly Robertson
  • , Imogen Caldwell
  • , Georgina Ryland
  • , Javad Saghebi
  • , Zahra Sabahi
  • , Jing Xie
  • , Rachel Koldej
    • Michael Dickinson

Research output: Contribution to journal › Article › peer-review

58   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry